China-based biopharmaceutical company Suzhou Ribo Life Science Co Ltd (HK:06938) and its Swedish subsidiary Ribocure Pharmaceuticals AB (collectively referred to as Ribo) announced on Monday the submission of a Phase I Clinical Trial Application in the European Union for SR122, a dual GalNAc conjugated siRNA therapeutic being developed for the treatment of dyslipidaemia, including severe hypertriglyceridemia (sHTG) and mixed dyslipidaemia.

As Ribo progresses the Phase II clinical studies of RBD5044 -- its core lipid asset which it claims to be the world's second-most advanced ApoC3-targeting siRNA -- in Europe and China, this filing marks a further upgrade to its lipid pipeline strategy.

SR122 simultaneously targets ApoC3 and PCSK9, two clinically validated pathways that play complementary roles in lipid metabolism. By addressing both triglyceride-rich lipoproteins and low-density lipoprotein cholesterol (LDL-C), SR122 has the potential to provide a differentiated treatment approach with durable improvements across multiple lipid parameters and cardiometabolic risk factors, Ribo said.

The Phase 1 clinical trial is a randomised, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered SR122 in healthy participants. The study will provide the first clinical evaluation of the dual targeting SR122 approach in humans and generate key data to support further development.